Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Study Evaluating the Efficacy and Safety of Novel Non-Opioid SRP-001 in Acute Pain After Molar Extraction

12. November 2026 aktualisiert von: South Rampart Pharma, Inc.

A Phase 2 Randomized, Double-blind, Placebo-controlled Study Assessing Analgesic Efficacy and Safety of the Novel Non-opioid SRP-001 Compared to Placebo in Patients With Moderate-to-severe Acute Postoperative Pain After Impacted Third Mandibular Molar Extraction

This study tests whether a single oral dose of SRP-001 (2,000 mg), a non-opioid drug, relieves moderate-to-severe pain after surgery to remove impacted third molars (wisdom teeth), compared with placebo. It also evaluates safety and how the body processes the drug.

Studienübersicht

Detaillierte Beschreibung

This is a single-center, randomized, double-blind, placebo-controlled, parallel-group Phase 2 study evaluating the analgesic efficacy, onset of action, pharmacokinetics, and safety of a single oral dose of SRP-001 (2,000 mg oral suspension) compared to matching placebo in 130 adult participants experiencing moderate-to-severe acute postoperative pain (NPRS ≥ 5 and categorical pain ≥ 2 within 4.5 hours) following extraction of two or more third molars (including at least two bone-impacted mandibular molars). Participants remain in the clinical research unit for 12 hours post-dose for serial efficacy, double-stopwatch onset, safety, and pharmacokinetic assessments, followed by 24-hour rescue diary tracking (two-tiered rescue: ibuprofen 400 mg, then oxycodone 5 mg if needed) and an in-person safety follow-up visit on Day 8 (± 2 days).

Studientyp

Interventionell

Einschreibung (Geschätzt)

130

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

  • Name: CenExel JBR Recruiting

Studienorte

    • Utah
      • Salt Lake City, Utah, Vereinigte Staaten, 84107
        • CenExel JBR Clinical Research
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 50 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Is male or female ≥ 18 and ≤ 50 years of age.
  • Requires extraction of 2 or more third molars. At least 2 of the third molars must be a fully or partially bone impacted mandibular molar.
  • Experiences moderate-to-severe pain defined as a score ≥ 2 on the 4-point categorical scale, and a score of ≥ 5 measured by the 0-10 Numeric Pain Rating Scale (NPRS) within 4.5 hours after surgery.
  • Has a body weight ≥ 45 kg and a body mass index (BMI) ≤ 35 kg/m2.
  • Female subjects of child-bearing potential must have used an acceptable method of contraception for at least 30 days prior to randomization and agree to continue use until at least 48 hours post-discharge from the clinic. To be considered not of child-bearing potential, females must be surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal (defined as no menses for 12 months without an alternative medical cause).
  • Free of clinically significant abnormal findings as determined by medical history, physical examination, vital signs, and laboratory tests.
  • Able to provide written informed consent.
  • Is willing and able to comply with study requirements (including diet and smoking restrictions), complete the pain evaluations, remain at the study site for 12 hours post-dose on Day 1, and complete an in-person follow-up visit on Day 8 (± 2 days)

Exclusion Criteria:

  • Known hypersensitivity or allergy to acetaminophen, NSAIDs (including ibuprofen), aspirin, study drug ingredients, anesthetics, or antibiotics.
  • History of active or previous peptic ulceration, gastrointestinal bleeding or perforation, heart failure, renal impairment, uncontrolled hypertension, exercise-induced asthma, nasal polyps, or chronic rhinitis; or history or presence of hepatic impairment, or clinically significant baseline laboratory abnormalities at Screening, defined as serum ALT or AST > 1.5× the Upper Limit of Normal (ULN), or total bilirubin > 1.5× ULN (unless attributable to documented Gilbert's syndrome), uncontrolled hypertension, exercise-induced asthma, nasal polyps, or chronic rhinitis.
  • Complications from tooth extraction resulting in a "severe" surgical trauma rating.
  • Dental surgery within 60 days prior to Day 1.
  • Positive urine drug screen or alcohol breathalyzer test.
  • Positive pregnancy test (serum at screening, urine pre-surgery on Day 1) or lactating.
  • Known history or suspected (in the opinion of the investigator) of alcoholism or drug abuse within 2 years.
  • Concomitant medications that confound pain assessment. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) are permitted if on a stable dose for ‭≥ 4 weeks prior to Screening.‬‬‬‬‬‬‬‬‬‬‬
  • History of chronic use (defined as daily use for > 2 weeks within 6 months) of NSAIDs, opiates, or glucocorticoids for any condition within 6 months prior to dosing.
  • Difficulty swallowing oral medication.
  • Investigational drug exposure within 30 days or 5 half-lives.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: SRP-001

SRP-001 Single Oral Suspension dose of 2,000 mg

SRP-001 Oral Suspension

Placebo-Komparator: Matching Placebo for SRP-001

Matching Placebo for SRP-001 Oral Suspension

Matching Placebo for SRP-001 Oral Suspension

Andere Namen:
  • Kontrolle

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Sum of Pain Intensity Differences Over 0 to 6 Hours (SPID0-6)
Zeitfenster: 0 to 6 hours post-dose

Time-weighted sum of pain intensity differences from baseline over 0 to 6 hours post-dose, assessed using the 0-10 Numeric Pain Rating Scale (NPRS scale 0 -10 higher being worse) comparing SRP-001 (2,000 mg) to placebo.

0 to 6 hours post-dose

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time-Weighted Sum of Pain Intensity Differences Over 0 to 2, 0 to 4, and 0 to 8 Hours (SPID0-2, SPID0-4, SPID0-8)
Zeitfenster: 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose

Time-weighted sum of pain intensity differences from baseline over 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose assessed on the 0-10 NPRS (higher being worse)

0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose
Sum of pain relief (TOTPAR)
Zeitfenster: O to 2, 0 to 4, 0 to 6 and 0-8 hours.

Sum of pain relief (TOTPAR) from 0 to 2 (TOTPAR0-2), 0 to 4 (TOTPAR0-4), 0 to 6 hours (TOTPAR0-6), and 0 to 8 (TOTPAR0-8) post dose.

O to 2, 0 to 4, 0 to 6 and 0-8 hours.
Time to a ≥1-Point Reduction in Numeric Pain Rating Scale (T1PMPR)
Zeitfenster: 0 to 8 hours post-dose

Time from study drug administration to a ≥1-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments.

0 to 8 hours post-dose
Time to a ≥2-Point Reduction in Numeric Pain Rating Scale (T2PMPR)
Zeitfenster: 0 to 8 hours post-dose

Time from study drug administration to a ≥2-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments.

0 to 8 hours post-dose
Time to first use of rescue medication
Zeitfenster: 0 - 6, 0-8, 0-24 hours post dose.

Rescue medication time for SRP-001 compared with placebo

0 - 6, 0-8, 0-24 hours post dose.
Total rescue medication consumption
Zeitfenster: 0 - 6, 0-8, 0-24 hours post dose.

Total rescue medication consumption for SRP-001 compared with placebo

0 - 6, 0-8, 0-24 hours post dose.
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Zeitfenster: Day 1 through Follow-up Visit (Day 8 ± 2 days)

Safety as assessed by number of participants with AEs and SAEs for SRP-001 compared with placebo and relationship to study medication

Day 1 through Follow-up Visit (Day 8 ± 2 days)
Pain intensity difference (PID) using the 11-point numeric pain rating scale (NPRS)
Zeitfenster: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dose

Pain intensity difference (PID) Scale is -10 to 10 (higher is better)

0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dose
Patient's global evaluation of study drug using a 5 point categorical scale
Zeitfenster: Up to 6 hours post dose

Patient's global evaluation of study drug immediately before the first dose of rescue medication, or at early termination (whichever occurs first) using 5 point scale where 0=poor o 4=excellent

Up to 6 hours post dose
Number of participants with clinically significant abnormalities in laboratory abnormalities
Zeitfenster: Screening, Day 1 pre-surgery and follow-up visit, Day 8 ± 2

Number of participants with laboratory values judged clinically significant by the investigator in the following panels:

Liver function tests (ALT, AST, bilirubin, alkaline phosphatase) Renal function tests (creatinine, BUN) Hematology parameters (CBC with differential)

Screening, Day 1 pre-surgery and follow-up visit, Day 8 ± 2
Maximum Observed Plasma Concentration (CMax) of SRP-001
Zeitfenster: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

CMax of SRP001 following a single 2,000mg oral dose, obtained directly from the plasma concentration data

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Time to maximum observed plasma concentration (Tmax) of SRP-001
Zeitfenster: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

Tmax of SRP-001 following a single 2,000mg oral dose, obtained directly from the plasma concentration-time data

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Area under the plasma concentration-time curve from 0-12 hours (AUC0-12) of SRP-001
Zeitfenster: Pre-dose through 12 hours post-dose

AUC0-12 of SRP-001 following a single 2,000mg oral dose.

Pre-dose through 12 hours post-dose
Area under the plasma concentration time curve from time 0 to the last measurable concentration (AUC0-t) of SRP-001
Zeitfenster: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

AUC0-t of SRP001 following a single 2,000mg oral dose

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Area under the plasma concentration time curve from time 0 extrapolated to infinity (AUC0-inf) of SRP-001
Zeitfenster: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

AUC0-inf of SRP-001 following a single 2,000mg oral dose

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Terminal elimination half life (t 1/2) of SRP-001
Zeitfenster: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

t 1/2 of SRP-001 following a single 2,000mg oral dose

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Apparent oral clearance (CL/F) of SRP-001
Zeitfenster: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

CL/F of SRP-001 following a single 2,000mg oral dose

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Apparent volume of distribution during the terminal phase (Vx/F) of SRP-001
Zeitfenster: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

Vz/F of SRP-001 following a single 2,000mg oral dose

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
Pain relief Difference (PR) using the 11-point numeric pain rating scale (NPRS)
Zeitfenster: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

Pain relief difference (PR)

Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time to first perceptible relief and time to confirmed perceptible pain relief
Zeitfenster: 0-4.5 hours post dose

TPPR and TCPR via stopwatch 1

0-4.5 hours post dose
Time to meaningful relief
Zeitfenster: 0-4.5 hours post dose

TMPR via Stopwatch 2

0-4.5 hours post dose
Time to complete pain relief
Zeitfenster: 0 to 8 hours post-dose

TCOMPR, NPRS = 0

0 to 8 hours post-dose

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Todd M Bertoch, MD, CenExel JBR Clinical Research

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

30. November 2026

Primärer Abschluss (Geschätzt)

28. Februar 2027

Studienabschluss (Geschätzt)

28. Februar 2027

Studienanmeldedaten

Zuerst eingereicht

4. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. November 2026

Zuerst gepostet (Tatsächlich)

18. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren